Read by QxMD icon Read

Weekly paclitaxel

Gabriella Ferrandina, Giacomo Corrado, Giuseppe Vitrano, Valerio Gallotta, Eleonora Palluzzi, Mariagrazia Distefano, Giovanni Scambia
PURPOSE: The role of dose-dense schedules in the neo-adjuvant treatment (NACT) of locally advanced cervical cancer (LACC) has been reported. This phase II study investigated activity of dose-dense paclitaxel/platinum before radical surgery (RS) in LACC patients. METHODS: The primary end-point was the rate of optimal pathological response (OPR: pathological complete/microscopic response). NACT (paclitaxel: 80 mg/m2 ) and carboplatin (AUC 2) were administered for 6 weeks...
December 1, 2018: Cancer Chemotherapy and Pharmacology
Sho Sato, Chikara Kunisaki, Yusaku Tanaka, Kei Sato, Hiroshi Miyamoto, Norio Yukawa, Yoshiro Fujii, Jun Kimura, Ryo Takagawa, Masazumi Takahashi, Takashi Kosaka, Hirotoshi Akiyama, Yusuke Saigusa, Masataka Taguri, Takeharu Yamanaka, Itaru Endo
BACKGROUND/AIM: Nanoparticle albumin-bound (nab)-paclitaxel has demonstrated antitumor activity against advanced gastric cancer. However, gastric cancer patients can be difficult to treat with the recommended dose because of the high incidence of adverse toxicities. The aim of this study was to evaluate the safety and effectiveness of low-dose nab-paclitaxel in a multicenter, single-arm, phase II study. PATIENTS AND METHODS: Treatment included low doses of 180 mg/m2 nab-paclitaxel administered on day 1 of each 21-day cycle...
December 2018: Anticancer Research
Arti Hurria, Enrique Soto-Perez-de-Celis, Suzette Blanchard, Peggy Burhenn, Christina Haeyoung Yeon, Yuan Yuan, Daneng Li, Vani Katheria, James Ross Waisman, Thehang H Luu, George Somlo, Anne M Noonan, Ty Lee, Nimit Sudan, Samuel Chung, Arnold Rotter, Anait Arsenyan, Abrahm Levi, Jennifer Choi, Andrea Rubalcava, Rachel Morrison, Joanne E Mortimer
INTRODUCTION: Phase II clinical trials including geriatric assessment (GA) measures are critical for improving the evidence base for older adults with cancer. We assessed the efficacy and tolerability of nab-paclitaxel in older adults with metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients aged ≥ 65 years with MBC and ≤ 1 previous line of chemotherapy received 100 mg of nab-paclitaxel on days 1, 8, and 15 of a 28-day cycle. A GA was completed pre-chemotherapy, and the validated Cancer and Aging Research Group (CARG) chemotherapy toxicity risk score was calculated...
October 16, 2018: Clinical Breast Cancer
Faye R Harris, Piyan Zhang, Lin Yang, Xiaonan Hou, Konstantinos Leventakos, Saravut J Weroha, George Vasmatzis, Irina V Kovtun
Ovarian cancer is most lethal gynecologic malignancy. About 75% of ovarian cancer patients relapse and/or develop chemo-resistant disease after initial response to standard-of-care treatment with platinum-based therapies. HER2 amplifications and overexpression in ovarian cancer are reported to vary, and responses to HER2 inhibitors have been poor. Next generation sequencing technologies in conjunction with testing using patient-derived xenografts (PDX) allow validation of personalized treatments. Using a whole-genome mate-pair next generation sequencing (MPseq) protocol, we identified several high grade serous ovarian cancers (HGS-OC) with DNA alterations in genes encoding members of the ERBB2 pathway...
November 30, 2018: Molecular Oncology
Begoña Martin-Castillo, Sonia Pernas, Joan Dorca, Isabel Álvarez, Susana Martínez, Jose Manuel Pérez-Garcia, Norberto Batista-López, César A Rodríguez-Sánchez, Kepa Amillano, Severina Domínguez, Maria Luque, Agostina Stradella, Idoia Morilla, Gemma Viñas, Javier Cortés, Elisabet Cuyàs, Sara Verdura, Álvaro Fernández-Ochoa, Salvador Fernández-Arroyo, Antonio Segura-Carretero, Jorge Joven, Elsa Pérez, Neus Bosch, Margarita Garcia, Eugeni López-Bonet, Samiha Saidani, Maria Buxó, Javier A Menendez
The METTEN study assessed the efficacy, tolerability, and safety of adding metformin to neoadjuvant chemotherapy plus trastuzumab in early HER2-positive breast cancer (BC). Women with primary, non-metastatic HER2-positive BC were randomized (1:1) to receive metformin (850 mg twice-daily) for 24 weeks concurrently with 12 cycles of weekly paclitaxel plus trastuzumab, followed by four cycles of 3-weekly FE75C plus trastuzumab (arm A), or equivalent regimen without metformin (arm B), followed by surgery. Primary endpoint was the rate of pathological complete response (pCR) in the per-protocol efficacy population...
November 2, 2018: Oncotarget
Yuko Kanbayashi, Kouichi Sakaguchi, Katsuhiko Nakatsukasa, Yoshimi Ouchi, Yusuke Tabuchi, Tomoko Yoshioka, Takeshi Ishikawa, Koichi Takayama, Tetsuya Taguchi
This retrospective study was undertaken to identify predictive factors for developing taxane acute pain syndrome (TAPS) and to determine new strategies for improving QoL in patients undergoing chemotherapy. Between November 2010 and May 2018, we enrolled 121 breast cancer patients at our outpatient chemotherapy center who were undergoing chemotherapy with nanoparticle albumin-bound paclitaxel (nab-PTX) every 3 weeks. Variables related to the development of TAPS were extracted from the patients' clinical records and used for regression analysis...
November 26, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Tiziana Prochilo, Alessandra Huscher, Federica Andreis, Mara Mirandola, Elisabetta Zaina, Barbara Pomentale, Chiara Pedrali, Laura Zanotti, Stefano Mutti, Alberto Zaniboni
BACKGROUND: The most effective agents in the treatment of breast cancer have as common side effect the hair loss. Some studies reported a reduction of hair loss with the use of the scalp cooling device. Indeed, it decreases the drug accumulation in the hair follicles. We report our preliminary experience with a scalp cooling device in reducing chemotherapy-induced alopecia and related distress in breast cancer patients undergoing adjuvant chemotherapy. METHODS: Hair loss grading and treatment tolerability were evaluated during chemotherapy every 21 days and 3 weeks after the last cycle of chemotherapy via Dean's scale by patients and operators and a comfort analogic scale by patients...
November 19, 2018: Reviews on Recent Clinical Trials
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Tsutomu Takashima, Shuhei Tomita, Hisashi Motomura, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: The lymphocyte-to-monocyte ratio (LMR) has been used as a parameter reflecting systemic inflammation in several tumors, and is reportedly associated with prognosis in cancer patients. In this study, we evaluated the predictive value of LMR for progression and chemosensitivity in breast cancer patients treated with preoperative chemotherapy. METHODS: LMR was evaluated in 239 patients with breast cancer treated with neoadjuvant chemotherapy (NAC) with 5-fluorouracil, epirubicin, and cyclophosphamide, followed by weekly paclitaxel with or without trastuzumab, and subsequent curative surgery...
November 19, 2018: BMC Cancer
Antonio González Martín, Amit M Oza, Andrew C Embleton, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Monique A Bertrand, Philip Beale, Andrés Cervantes, Emma Kent, Richard S Kaplan, Mahesh K B Parmar, Nana Scotto, Timothy J Perren
OBJECTIVE: In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. METHODS: Patients with stage IIB-IV or high-risk (grade 3/clear-cell) stage I-IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7...
November 15, 2018: Gynecologic Oncology
Akash Mathur, Naincy Rastogi, Dinesh Gurjar, Ramkrishna Sai, Arvind Lakesar, Hemant Malhotra
Background: Squamous cell carcinoma of head and neck (SCCHN) is one of the most common cancers seen in India and also the world. Majority of patients present in locally advanced (LA) disease where neoadjuvant combination chemotherapy with a taxane plus platinum with/without 5-Fluorouracil is the standard of care treatment. There are no/few prospective trials of weekly paclitaxel in SCCHN in spite of convincing evidence regarding safety and tolerability in other solid tumors such as breast, ovary, and lung carcinoma...
October 2018: South Asian Journal of Cancer
Yuko Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue, Yuka Fujita, Ryo Toyozawa, Tomoki Kimura, Kosuke Takahashi, Kazuo Nishikawa, Junji Kishimoto, Yoichi Nakanishi, Isamu Okamoto
OBJECTIVES: Chemoradiation regimens of greater efficacy are needed for patients with locally advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: In a phase I study, escalating doses of weekly nab-paclitaxel (40 or 50 mg/m2 ) were administered along with weekly carboplatin at an area under the curve (AUC) of 2 mg mL-1 min and concurrent radiotherapy with 60 Gy in 30 fractions to patients with locally advanced NSCLC. This concurrent phase was followed by a consolidation phase consisting of two 3-week cycles of nab-paclitaxel plus carboplatin...
November 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Konstantin H Dragnev, Jeremy D Whyman, Cynthia K Hahn, Peter E Kebbekus, Sarah F Kokko, Sunil M Bhatt, James R Rigas
Background: Rexinoids demonstrate anti-proliferative differentiation-inducing activity in multiple cancer types, including NSCLC. Prior studies have shown promising results when combining rexinoids with chemotherapy. This phase I/II study evaluates the tolerability and activity of a rexinoid, bexarotene, combined with weekly paclitaxel and monthly carboplatin. Methods: Patients with confirmed advanced stage IIIB or IV NSCLC and adequate organ function were enrolled...
September 2018: Journal of Thoracic Disease
Jun Xu, Steve Seung-Young Lee, Howon Seo, Liang Pang, Yearin Jun, Ruo-Yu Zhang, Zhong-Yin Zhang, Pilhan Kim, Wooin Lee, Stephen J Kron, Yoon Yeo
Current nanoparticle (NP) drug carriers mostly depend on the enhanced permeability and retention (EPR) effect for selective drug delivery to solid tumors. However, in the absence of a persistent EPR effect, the peritumoral endothelium can function as an access barrier to tumors and negatively affect the effectiveness of NPs. In recognition of the peritumoral endothelium as a potential barrier in drug delivery to tumors, poly(lactic-co-glycolic acid) (PLGA) NPs are modified with a quinic acid (QA) derivative, synthetic mimic of selectin ligands...
November 9, 2018: Small
Myra Barginear, Amylou C Dueck, Jacob B Allred, Craig Bunnell, Harvey J Cohen, Rachel A Freedman, Arti Hurria, Gretchen Kimmick, Jennifer G Le-Rademacher, Stuart Lichtman, Hyman B Muss, Lawrence N Shulman, M Sitiki Copur, David Biggs, Bhuvaneswari Ramaswamy, Jacqueline M Lafky, Aminah Jatoi
PURPOSE: A few previous studies report a direct relationship between older age and chemotherapy-induced neuropathy. This study further evaluated this adverse event's age-based risk. METHODS: CALGB 40101 investigated adjuvant paclitaxel (80 mg/m2 once per week or 175 mg/m2 every 2 weeks) in patients with breast cancer and served as a platform for the current study that investigated age-based differences in neuropathy. Grade 2 or worse neuropathy, as per Common Terminology Criteria for Adverse Events version 4, was the primary endpoint; patients were assessed at baseline, every 6 months for 2 years, and then annually for 15 years...
November 8, 2018: Oncologist
Jung-Yun Lee, Jeong-Yeol Park, Sang Yoon Park, Jeong-Won Lee, Jae Weon Kim, Yong Beom Kim, Dae Hoon Jeong, Kwang-Beom Lee, Tae-Hun Kim, In Ho Lee, Min Chul Choi, Ki Hyung Kim, Yong-Man Kim, Yong Jae Lee, Sokbom Kang, Eric Pujade-Lauraine
PURPOSE: To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. PATIENTS AND METHODS: We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice...
November 5, 2018: Gynecologic Oncology
Hiromichi Kawaida, Hiroshi Kono, Hidetake Amemiya, Ryou Saitou, Atsushi Yamamoto, Naohiro Hosomura, Mitsuaki Watanabe, Ayako Kimura, Shinji Furuya, Hiroki Shimizu, Hidenori Akaike, Yoshihiko Kawaguchi, Makoto Sudo, Jun Itakura, Hiroshi Hayakawa, Hiroko Shindo, E I Takahashi, Shinichi Takano, Mitsuharu Fukasawa, Shintaro Ichikawa, Hideki Fujii, Daisuke Ichikawa
BACKGROUND/AIM: Nab-paclitaxel plus gemcitabine (nab-P+Gem) is one of most reliable and effective regimens for borderline or unresectable pancreatic cancer (PC). However, the feasibility and clinical benefits of this regimen have never been evaluated for patients with recurrent PC after pancreatectomy. The aim of this study was to investigate the feasibility of combination therapy with nab-paclitaxel plus gemcitabine (nab-P+Gem) for patients with recurrent PC. PATIENTS AND METHODS: Twenty-two patients with recurrent PC received an intravenous infusion of nab-P (125 mg/m2 ) and Gem (1,000 mg/m2 ) on days 1, 8, and 15 of a 4-week cycle...
November 2018: Anticancer Research
Steven P Bisch, Akira Sugimoto, Michel Prefontaine, Monique Bertrand, Christine Gawlik, Stephen Welch, Jacob McGee
OBJECTIVE: To describe the frequency of clinically significant side effects associated with adjuvant intraperitoneal (IP) carboplatin and intravenous (IV) dose-dense paclitaxel chemotherapy for epithelial ovarian cancer (EOC). METHODS: Patients with stage II to IV EOC who underwent upfront cytoreductive surgery followed by adjuvant IP carboplatin (AUC 6) every 3 weeks with IV paclitaxel weekly at 80 mg/m2 were included. Side effects and the resulting changes in treatment are presented using univariate analysis and compared to major phase III RCTs...
October 2018: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
Koji Murono, Hiroshi Nagata, Kazuhiro Ishimaru, Shigenobu Emoto, Manabu Kaneko, Masaya Hiyoshi, Kazuhito Sasaki, Kensuke Otani, Yasutaka Shuno, Takeshi Nishikawa, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Kei Muro, Soichiro Ishihara
PURPOSE: Peritoneal carcinomatosis of colorectal cancer origin is associated with poor prognosis. With regard to ovarian, gastric, and pancreatic cancer, the safety and efficacy of intraperitoneal administration of paclitaxel (ip PTX) has been demonstrated. This drug can be administered easily and repeatedly through a catheter into the peritoneal cavity. In this phase I study, we evaluated the safety of ip PTX combined with 5-fluorouracil, folinic acid, oxaliplatin, and bevacizumab (mFOLFOX6-bevacizumab) or capecitabine, oxaliplatin, and bevacizumab (CapeOX-bevacizumab) for colorectal cancer with peritoneal metastasis...
November 1, 2018: Cancer Chemotherapy and Pharmacology
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, Aung Naing, Vivek Subbiah, Helen J Huang, Daniel D Karp, Apostolia M Tsimberidou, Ralph G Zinner, Wen-Jen Hwu, Milind Javle, Sapna P Patel, Mimi I Hu, Gauri R Varadhachary, Anthony P Conley, Nishma M Ramzanali, Veronica R Holley, Razelle Kurzrock, Funda Meric-Bernstam, Young Kwang Chae, Kevin B Kim, Gerald S Falchook, Filip Janku
BACKGROUND: BRAF inhibitors are effective against selected BRAFV600 -mutated tumors. Preclinical data suggest that BRAF inhibition in conjunction with chemotherapy has increased therapeutic activity. METHODS: Patients with advanced cancers and BRAF mutations were enrolled into a dose-escalation study (3+3 design) to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). RESULTS: Nineteen patients with advanced cancers and BRAF mutations were enrolled and received vemurafenib (480-720 mg orally twice a day), carboplatin (area under the curve [AUC] 5-6 intravenously every 3 weeks), and paclitaxel (100-135 mg/m2 intravenously every 3 weeks)...
November 1, 2018: Cancer
Junya Morita, Toru Aoyama, Shinya Amano, Yukio Maezawa, Sho Sawazaki, Masakatsu Numata, Tsutomu Sato, Yukihiro Ozawa, Takashi Oshima, Norio Yukawa, Yasushi Rino, Munetaka Masuda
A 59-year-old woman was diagnosed with advanced gastric cancer with para-aortic and Virchow's lymph node metastases (L, Less, type 2, tub1, cT3N2H0P0M1[LYM: #16, Virchow's]). Four courses of S-1(80mg/m / 2, days 1-21)and CDDP(60mg/ m2, day 8)were administered. After the chemotherapy, CT showed that the primary tumor and para-aortic and Virchow's lymph nodes had reduced in size. The clinical stage was ycT3N1H0P0M0, stage III A. The patient underwent distalgastrectomy, D2 dissection, and sampling of the para-aortic lymph nodes(#16b1lat, #16a2int)...
October 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"